Sun Pharmaceutical Industries on Tuesday announced a senior management rejig, with India and emerging markets head Kal Sundaram will now be responsible for Japan and China businesses besides the company's strategic initiatives.
Announcing changes during an earnings call on the first quarter results,
Sun Pharma Managing Director Dilip Shanghvi said Kirti Ganorkar, who was heading the global business development function, will now head the India formulations business.
Further, Aalok Shanghvi -- who is currently Senior VP - Emerging Markets & Global R&D -- will have additional responsibility for generic business development in addition to his current role.
"We will look for a fresh recruitment for the branded business development function...," Shanghvi said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
